NEW YORK, Nov. 2 — Genicon Sciences has closed a deal to allow the Genomics Institute of the Novartis Research Foundation to use its proprietary Resonance Light Scattering technology, according to Genicon. 

The partners will cooperatively develop and commercialize the technology, which Genicon has designed for stable, highly sensitive signal generation and detection in a range of molecular assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.